APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonspecific Endonuclease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nonspecific Endonuclease Market Outlook and Growth Opportunities 2026

27 December 2025198 pages

Choose your research edition.

Industry ResearchNonspecific Endonuclease Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonspecific Endonuclease Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nonspecific Endonuclease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonspecific Endonuclease Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonspecific Endonuclease Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nonspecific Endonuclease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nonspecific Endonuclease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nonspecific Endonuclease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nonspecific Endonuclease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nonspecific Endonuclease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nonspecific Endonuclease market include Yisheng Biotechnology (Shanghai) Co., Ltd., Shanghai Zhudian Biotechnology Co., Ltd., Thermo Fisher Scientific Inc., KACTUS, GenScript, Shanghai Biyuntian Biotechnology Co., Ltd., TransGen Biotech, RayBiotech, Inc. and ACROBiosystems Group, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nonspecific Endonuclease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nonspecific Endonuclease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nonspecific Endonuclease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nonspecific Endonuclease market.

Nonspecific Endonuclease Segment by Company

Yisheng Biotechnology (Shanghai) Co., Ltd.

Shanghai Zhudian Biotechnology Co., Ltd.

Thermo Fisher Scientific Inc.

KACTUS

GenScript

Shanghai Biyuntian Biotechnology Co., Ltd.

TransGen Biotech

RayBiotech, Inc.

ACROBiosystems Group

AbMole BioScience

Nonspecific Endonuclease Segment by Type

100kU

25kU

50kU

5kU

＞100kU

Nonspecific Endonuclease Segment by Application

Biological Laboratory

University Research Room

Others

Nonspecific Endonuclease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nonspecific Endonuclease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nonspecific Endonuclease key companies, revenue, market share, and recent developments.

3. To split the Nonspecific Endonuclease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nonspecific Endonuclease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nonspecific Endonuclease significant trends, drivers, influence factors in global and regions.

6. To analyze Nonspecific Endonuclease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonspecific Endonuclease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonspecific Endonuclease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonspecific Endonuclease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nonspecific Endonuclease industry.

Chapter 3: Detailed analysis of Nonspecific Endonuclease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nonspecific Endonuclease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nonspecific Endonuclease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nonspecific Endonuclease Industry Trends Table 2. Nonspecific Endonuclease Industry Drivers Table 3. Nonspecific Endonuclease Industry Opportunities and Challenges Table 4. Nonspecific Endonuclease Industry Restraints Table 5. Global Nonspecific Endonuclease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nonspecific Endonuclease Revenue Share by Company (2021-2026) Table 7. Global Nonspecific Endonuclease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nonspecific Endonuclease Key Company Manufacturing Base & Headquarters Table 9. Global Nonspecific Endonuclease Company, Product Type & Application Table 10. Global Nonspecific Endonuclease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nonspecific Endonuclease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 100kU Table 15. Significant Companies of 25kU Table 16. Significant Companies of 50kU Table 17. Significant Companies of 5kU Table 18. Significant Companies of ＞100kU Table 19. Global Nonspecific Endonuclease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Nonspecific Endonuclease Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Nonspecific Endonuclease Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Nonspecific Endonuclease Sales Value Share by Type (2021-2026) Table 23. Global Nonspecific Endonuclease Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Biological Laboratory Table 25. Significant Companies of University Research Room Table 26. Significant Companies of Others Table 27. Global Nonspecific Endonuclease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Nonspecific Endonuclease Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Nonspecific Endonuclease Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Nonspecific Endonuclease Sales Value Share by Application (2021-2026) Table 31. Global Nonspecific Endonuclease Sales Value Share by Application (2027-2032) Table 32. Global Nonspecific Endonuclease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Nonspecific Endonuclease Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Nonspecific Endonuclease Sales Value Share by Region (2021-2026) Table 35. Global Nonspecific Endonuclease Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Nonspecific Endonuclease Sales Value Share by Region (2027-2032) Table 37. Global Nonspecific Endonuclease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nonspecific Endonuclease Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Nonspecific Endonuclease Sales Value Market Share by Country (2021-2026) Table 40. Global Nonspecific Endonuclease Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Nonspecific Endonuclease Sales Value Market Share by Country (2027-2032) Table 42. Yisheng Biotechnology (Shanghai) Co., Ltd. Company Information Table 43. Yisheng Biotechnology (Shanghai) Co., Ltd. Business Overview Table 44. Yisheng Biotechnology (Shanghai) Co., Ltd. Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Yisheng Biotechnology (Shanghai) Co., Ltd. Nonspecific Endonuclease Product Portfolio Table 46. Yisheng Biotechnology (Shanghai) Co., Ltd. Recent Development Table 47. Shanghai Zhudian Biotechnology Co., Ltd. Company Information Table 48. Shanghai Zhudian Biotechnology Co., Ltd. Business Overview Table 49. Shanghai Zhudian Biotechnology Co., Ltd. Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Shanghai Zhudian Biotechnology Co., Ltd. Nonspecific Endonuclease Product Portfolio Table 51. Shanghai Zhudian Biotechnology Co., Ltd. Recent Development Table 52. Thermo Fisher Scientific Inc. Company Information Table 53. Thermo Fisher Scientific Inc. Business Overview Table 54. Thermo Fisher Scientific Inc. Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Thermo Fisher Scientific Inc. Nonspecific Endonuclease Product Portfolio Table 56. Thermo Fisher Scientific Inc. Recent Development Table 57. KACTUS Company Information Table 58. KACTUS Business Overview Table 59. KACTUS Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. KACTUS Nonspecific Endonuclease Product Portfolio Table 61. KACTUS Recent Development Table 62. GenScript Company Information Table 63. GenScript Business Overview Table 64. GenScript Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. GenScript Nonspecific Endonuclease Product Portfolio Table 66. GenScript Recent Development Table 67. Shanghai Biyuntian Biotechnology Co., Ltd. Company Information Table 68. Shanghai Biyuntian Biotechnology Co., Ltd. Business Overview Table 69. Shanghai Biyuntian Biotechnology Co., Ltd. Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Shanghai Biyuntian Biotechnology Co., Ltd. Nonspecific Endonuclease Product Portfolio Table 71. Shanghai Biyuntian Biotechnology Co., Ltd. Recent Development Table 72. TransGen Biotech Company Information Table 73. TransGen Biotech Business Overview Table 74. TransGen Biotech Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. TransGen Biotech Nonspecific Endonuclease Product Portfolio Table 76. TransGen Biotech Recent Development Table 77. RayBiotech, Inc. Company Information Table 78. RayBiotech, Inc. Business Overview Table 79. RayBiotech, Inc. Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. RayBiotech, Inc. Nonspecific Endonuclease Product Portfolio Table 81. RayBiotech, Inc. Recent Development Table 82. ACROBiosystems Group Company Information Table 83. ACROBiosystems Group Business Overview Table 84. ACROBiosystems Group Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. ACROBiosystems Group Nonspecific Endonuclease Product Portfolio Table 86. ACROBiosystems Group Recent Development Table 87. AbMole BioScience Company Information Table 88. AbMole BioScience Business Overview Table 89. AbMole BioScience Nonspecific Endonuclease Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. AbMole BioScience Nonspecific Endonuclease Product Portfolio Table 91. AbMole BioScience Recent Development Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Nonspecific Endonuclease Product Image Figure 2. Global Nonspecific Endonuclease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonspecific Endonuclease Market Size (2021-2032) & (US$ Million) Figure 4. Global Nonspecific Endonuclease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 100kU Image Figure 8. 25kU Image Figure 9. 50kU Image Figure 10. 5kU Image Figure 11. ＞100kU Image Figure 12. Global Nonspecific Endonuclease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Nonspecific Endonuclease Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Nonspecific Endonuclease Sales Value Share by Type (2021-2032) Figure 15. Biological Laboratory Image Figure 16. University Research Room Image Figure 17. Others Image Figure 18. Global Nonspecific Endonuclease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nonspecific Endonuclease Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Nonspecific Endonuclease Sales Value Share by Application (2021-2032) Figure 21. Global Nonspecific Endonuclease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Nonspecific Endonuclease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Nonspecific Endonuclease Sales Value (2021-2032) & (US$ Million) Figure 24. North America Nonspecific Endonuclease Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Nonspecific Endonuclease Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Nonspecific Endonuclease Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Nonspecific Endonuclease Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Nonspecific Endonuclease Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Nonspecific Endonuclease Sales Value (2021-2032) & (US$ Million) Figure 30. South America Nonspecific Endonuclease Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Nonspecific Endonuclease Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Nonspecific Endonuclease Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Nonspecific Endonuclease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • 100kU
  • 25kU
  • 50kU
  • 5kU
  • ＞100kU
Applications
  • Biological Laboratory
  • University Research Room
  • Others
Companies covered
  • Yisheng Biotechnology (Shanghai) Co., Ltd.
  • Shanghai Zhudian Biotechnology Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • KACTUS
  • GenScript
  • Shanghai Biyuntian Biotechnology Co., Ltd.
  • TransGen Biotech
  • RayBiotech, Inc.
  • ACROBiosystems Group
  • AbMole BioScience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nonspecific Endonuclease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nonspecific Endonuclease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nonspecific Endonuclease Market Dynamics
  1. 2.1 Nonspecific Endonuclease Industry Trends
  2. 2.2 Nonspecific Endonuclease Industry Drivers
  3. 2.3 Nonspecific Endonuclease Industry Opportunities and Challenges
  4. 2.4 Nonspecific Endonuclease Industry Restraints
3 Nonspecific Endonuclease Market by Company
  1. 3.1 Global Nonspecific Endonuclease Company Revenue Ranking in 2025
  2. 3.2 Global Nonspecific Endonuclease Revenue by Company (2021-2026)
  3. 3.3 Global Nonspecific Endonuclease Company Ranking (2024-2026)
  4. 3.4 Global Nonspecific Endonuclease Company Manufacturing Base and Headquarters
  5. 3.5 Global Nonspecific Endonuclease Company Product Type and Application
  6. 3.6 Global Nonspecific Endonuclease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nonspecific Endonuclease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nonspecific Endonuclease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nonspecific Endonuclease Market by Type
  1. 4.1 Nonspecific Endonuclease Type Introduction
  2. 4.1.1 100kU
  3. 4.1.2 25kU
  4. 4.1.3 50kU
  5. 4.1.4 5kU
  6. 4.1.5 ＞100kU
  7. 4.2 Global Nonspecific Endonuclease Sales Value by Type
  8. 4.2.1 Global Nonspecific Endonuclease Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Nonspecific Endonuclease Sales Value by Type (2021-2032)
  10. 4.2.3 Global Nonspecific Endonuclease Sales Value Share by Type (2021-2032)
5 Nonspecific Endonuclease Market by Application
  1. 5.1 Nonspecific Endonuclease Application Introduction
  2. 5.1.1 Biological Laboratory
  3. 5.1.2 University Research Room
  4. 5.1.3 Others
  5. 5.2 Global Nonspecific Endonuclease Sales Value by Application
  6. 5.2.1 Global Nonspecific Endonuclease Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nonspecific Endonuclease Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nonspecific Endonuclease Sales Value Share by Application (2021-2032)
6 Nonspecific Endonuclease Regional Value Analysis
  1. 6.1 Global Nonspecific Endonuclease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nonspecific Endonuclease Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nonspecific Endonuclease Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nonspecific Endonuclease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nonspecific Endonuclease Sales Value (2021-2032)
  7. 6.3.2 North America Nonspecific Endonuclease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nonspecific Endonuclease Sales Value (2021-2032)
  10. 6.4.2 Europe Nonspecific Endonuclease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nonspecific Endonuclease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nonspecific Endonuclease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nonspecific Endonuclease Sales Value (2021-2032)
  16. 6.6.2 South America Nonspecific Endonuclease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nonspecific Endonuclease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nonspecific Endonuclease Sales Value Share by Country, 2025 VS 2032
7 Nonspecific Endonuclease Country-level Value Analysis
  1. 7.1 Global Nonspecific Endonuclease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nonspecific Endonuclease Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nonspecific Endonuclease Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nonspecific Endonuclease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nonspecific Endonuclease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nonspecific Endonuclease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nonspecific Endonuclease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yisheng Biotechnology (Shanghai) Co., Ltd.
  2. 8.1.1 Yisheng Biotechnology (Shanghai) Co., Ltd. Company Information
  3. 8.1.2 Yisheng Biotechnology (Shanghai) Co., Ltd. Business Overview
  4. 8.1.3 Yisheng Biotechnology (Shanghai) Co., Ltd. Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yisheng Biotechnology (Shanghai) Co., Ltd. Nonspecific Endonuclease Product Portfolio
  6. 8.1.5 Yisheng Biotechnology (Shanghai) Co., Ltd. Recent Developments
  7. 8.2 Shanghai Zhudian Biotechnology Co., Ltd.
  8. 8.2.1 Shanghai Zhudian Biotechnology Co., Ltd. Company Information
  9. 8.2.2 Shanghai Zhudian Biotechnology Co., Ltd. Business Overview
  10. 8.2.3 Shanghai Zhudian Biotechnology Co., Ltd. Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Zhudian Biotechnology Co., Ltd. Nonspecific Endonuclease Product Portfolio
  12. 8.2.5 Shanghai Zhudian Biotechnology Co., Ltd. Recent Developments
  13. 8.3 Thermo Fisher Scientific Inc.
  14. 8.3.1 Thermo Fisher Scientific Inc. Company Information
  15. 8.3.2 Thermo Fisher Scientific Inc. Business Overview
  16. 8.3.3 Thermo Fisher Scientific Inc. Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Inc. Nonspecific Endonuclease Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Inc. Recent Developments
  19. 8.4 KACTUS
  20. 8.4.1 KACTUS Company Information
  21. 8.4.2 KACTUS Business Overview
  22. 8.4.3 KACTUS Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 KACTUS Nonspecific Endonuclease Product Portfolio
  24. 8.4.5 KACTUS Recent Developments
  25. 8.5 GenScript
  26. 8.5.1 GenScript Company Information
  27. 8.5.2 GenScript Business Overview
  28. 8.5.3 GenScript Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GenScript Nonspecific Endonuclease Product Portfolio
  30. 8.5.5 GenScript Recent Developments
  31. 8.6 Shanghai Biyuntian Biotechnology Co., Ltd.
  32. 8.6.1 Shanghai Biyuntian Biotechnology Co., Ltd. Company Information
  33. 8.6.2 Shanghai Biyuntian Biotechnology Co., Ltd. Business Overview
  34. 8.6.3 Shanghai Biyuntian Biotechnology Co., Ltd. Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Biyuntian Biotechnology Co., Ltd. Nonspecific Endonuclease Product Portfolio
  36. 8.6.5 Shanghai Biyuntian Biotechnology Co., Ltd. Recent Developments
  37. 8.7 TransGen Biotech
  38. 8.7.1 TransGen Biotech Company Information
  39. 8.7.2 TransGen Biotech Business Overview
  40. 8.7.3 TransGen Biotech Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 TransGen Biotech Nonspecific Endonuclease Product Portfolio
  42. 8.7.5 TransGen Biotech Recent Developments
  43. 8.8 RayBiotech, Inc.
  44. 8.8.1 RayBiotech, Inc. Company Information
  45. 8.8.2 RayBiotech, Inc. Business Overview
  46. 8.8.3 RayBiotech, Inc. Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 RayBiotech, Inc. Nonspecific Endonuclease Product Portfolio
  48. 8.8.5 RayBiotech, Inc. Recent Developments
  49. 8.9 ACROBiosystems Group
  50. 8.9.1 ACROBiosystems Group Company Information
  51. 8.9.2 ACROBiosystems Group Business Overview
  52. 8.9.3 ACROBiosystems Group Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ACROBiosystems Group Nonspecific Endonuclease Product Portfolio
  54. 8.9.5 ACROBiosystems Group Recent Developments
  55. 8.10 AbMole BioScience
  56. 8.10.1 AbMole BioScience Company Information
  57. 8.10.2 AbMole BioScience Business Overview
  58. 8.10.3 AbMole BioScience Nonspecific Endonuclease Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbMole BioScience Nonspecific Endonuclease Product Portfolio
  60. 8.10.5 AbMole BioScience Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst